A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting · NCT05757102 · Interventional (participants receive a specific treatment) · Lead sponsor: GlaxoSmithKline

View the official record on ClinicalTrials.gov →

Interventions studied

ELLIPTAFF/UMEC/VIFF/VI

What this trial is about

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Who can take part

Age range

12 Years to 17 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Phase 3

Study type

Interventional (participants receive a specific treatment)

Inclusion criteria

Participant must be 12 to 17 years of age (inclusive), at the time of signing the informed consent/assent.
Participants who have a diagnosis of asthma as defined by the National Institutes of Health \[NIH, 2020\] at least 1 year prior to Visit 0.
Participants who have required daily Inhaled corticosteroids (ICS)/ Long-Acting Beta2-Agonist (LABA) treatment for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total ICS dose of \>250 to \<=500 microgram (mcg)/day fluticasone propionate, or equivalent).
In the 1 year prior to Visit 1: A documented healthcare contact for acute asthma symptoms; OR A documented temporary change in asthma therapy for acute asthma symptoms, according to a prespecified asthma action plan (or equivalent).
Participants with inadequately controlled asthma (ACQ-6 score ≥1.5) at Visit 1, despite ICS/LABA maintenance therapy.
A best pre-bronchodilator FEV1 \>40% to \<=90% of the predicted normal value and a ≥12% increase in FEV1 with albuterol/salbutamol at Visit 1. Predicted values will be based on the European Respiratory Society (ERS) Global Lung Function Initiative.

Exclusion criteria

Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.
Any asthma exacerbation requiring a change in maintenance asthma therapy and/or the use of systemic corticosteroids for at least 3 days in the 6 weeks prior to Visit 1. (Participants requiring a temporary change in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1 provided that, at the Investigator's discretion, the participant's condition is stable after they have resumed their pre-exacerbation maintenance asthma therapy (without modification), returned to their baseline asthma status and they are considered appropriate for enrollment into this study of up to 6 months duration)
History of Life-threatening Asthma
Participants with current evidence of active pulmonary diseases or abnormalities other than asthma (e.g., pneumonia, active tuberculosis, significant bronchiectasis, etc.).
Current smokers and users of other inhaled products for recreation with or without nicotine (defined as participants who use cigarettes, e-cigarettes, other/vaping-related devices, cigars or pipe tobacco\]) within 12 months prior to Visit 1.

Where it is running

60 locations listed across 16 US states.

GSK Investigational Site - Birmingham, Alabama, United States
GSK Investigational Site - Mobile, Alabama, United States
GSK Investigational Site - Paradise Valley, Arizona, United States
GSK Investigational Site - Bakersfield, California, United States
GSK Investigational Site - Huntington Beach, California, United States
GSK Investigational Site - Mission Viejo, California, United States
GSK Investigational Site - Rolling Hills Estates, California, United States
GSK Investigational Site - Colorado Springs, Colorado, United States
GSK Investigational Site - Aventura, Florida, United States
GSK Investigational Site - Miami, Florida, United States
GSK Investigational Site - Miami, Florida, United States
GSK Investigational Site - Miami, Florida, United States
GSK Investigational Site - Savannah, Georgia, United States
GSK Investigational Site - Normal, Illinois, United States
GSK Investigational Site - Owensboro, Kentucky, United States
GSK Investigational Site - Columbia, Missouri, United States
GSK Investigational Site - Missoula, Montana, United States
GSK Investigational Site - The Bronx, New York, United States
GSK Investigational Site - Cincinnati, Ohio, United States
GSK Investigational Site - Cleveland, Ohio, United States
GSK Investigational Site - Dayton, Ohio, United States
GSK Investigational Site - Oklahoma City, Oklahoma, United States
GSK Investigational Site - Charleston, South Carolina, United States
GSK Investigational Site - Dallas, Texas, United States
GSK Investigational Site - Kerrville, Texas, United States
GSK Investigational Site - Plano, Texas, United States
GSK Investigational Site - Waco, Texas, United States
GSK Investigational Site - Milwaukee, Wisconsin, United States
GSK Investigational Site - Adana, Turkey (Türkiye)
GSK Investigational Site - Antalya, Turkey (Türkiye)
GSK Investigational Site - Ashkelon, Israel
GSK Investigational Site - Buenos Aires, Argentina
GSK Investigational Site - Buenos Aires, Argentina
GSK Investigational Site - Buenos Aires, Argentina
GSK Investigational Site - Buenos Aires, Argentina
GSK Investigational Site - Buenos Aires, Argentina
GSK Investigational Site - Cheongju Chungcheongbuk-do, South Korea
GSK Investigational Site - Córdoba, Argentina
GSK Investigational Site - Córdoba, Argentina
GSK Investigational Site - Guadalajara, Mexico
GSK Investigational Site - Gwangju, South Korea
GSK Investigational Site - Haifa, Israel
GSK Investigational Site - Haifa, Israel
GSK Investigational Site - Istanbul, Turkey (Türkiye)
GSK Investigational Site - Istanbul, Turkey (Türkiye)
GSK Investigational Site - Lanus, Argentina
GSK Investigational Site - Lo Barnechea, Chile
GSK Investigational Site - Lobos, Argentina
GSK Investigational Site - Lujan de Cuyo, Argentina
GSK Investigational Site - Mar del Plata, Argentina
GSK Investigational Site - Monterrey, Mexico
GSK Investigational Site - Petah Tikva, Israel
GSK Investigational Site - Rosario, Argentina
GSK Investigational Site - Rosario Provincia de Santa FE, Argentina
GSK Investigational Site - San Juan del Río, Mexico
GSK Investigational Site - San Miguel de Tucumán, Argentina
GSK Investigational Site - Santa Fe, Argentina
GSK Investigational Site - Santiago, Chile
GSK Investigational Site - Santiago, Chile
GSK Investigational Site - Seoul, South Korea

Showing 60 of 67 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →